Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
- Conditions
- Interventions
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT06186622
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States
A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06160414
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT06111521
- Locations
- 🇺🇸
ICON Early Clinical & Bioanalytical Solutions, Salt Lake City, Utah, United States
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-01-11
- Target Recruit Count
- 28
- Registration Number
- NCT06092931
- Locations
- 🇺🇸
ICON Phase 1 Clinic, Salt Lake City, Utah, United States
Statins in Patients With Spontaneous Intracerebral Hemorrhage
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Pomeranian Medical University Szczecin
- Target Recruit Count
- 153
- Registration Number
- NCT06094244
- Locations
- 🇵🇱
Pomeranian Medical University, Szczecin, West Pomeranian, Poland
Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
- Conditions
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06071442
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT06031454
- Locations
- 🇨🇳
the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Voxelotor CYP and Transporter Cocktail Interaction Study
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT05981365
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 49
- Registration Number
- NCT05954624
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou University of Chinese medicine, Guangzhou, China
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 15
- Registration Number
- NCT05912387
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.